ESG

Formerly Nature Wood Group, the forestry firm reports a surprise profit despite falling revenue after a complete change in ownership and leadership.

A successful demonstration of Revoltz's compact electric cargo vehicle to Israeli officials could signal a major shift in last-mile logistics.

A new AI-operated system called Beacon promises to transform chronic pain care by unifying patient data and easing the administrative burden on clinics.

A CETY affiliate moves its 2.2 MW Vermont plant through regulatory hurdles, but past setbacks, new technology, and financial questions loom large.

Capital Clean Energy Carriers Corp. orders three advanced LNG carriers, positioning itself to capitalize on a projected surge in global gas demand.

He helped land a Bible on the moon, but his final years were spent in state custody as his historic legacy became trapped in a bitter legal battle.

With a new HQ and $2M in contracts, Taoping is leveraging AI and government policy to modernize China's aging elevators, but faces investor scrutiny.

Ultragenyx's stock plummets after its Osteogenesis Imperfecta drug fails to reduce fractures, a major blow for patients and a test of the firm's pipeline.

A landmark journal issue introduces a new framework for facial rejuvenation, moving beyond outdated norms to embrace individualized, culturally sensitive care.

ConnectM's new modular battery isn't just for blackouts. It's an AI-driven gateway to lower energy bills and the virtual power plant of the future.

As its cash runway shortens, Longeveron's novel stem cell therapy gets a major boost with selection for a prestigious Alzheimer's health moonshot.

StimLabs secures FDA clearance for Theracor, the first-ever umbilical cord sheet device, offering new hope for patients with hard-to-heal chronic wounds.

INOVIO's promising non-surgical treatment for a rare disease faces FDA scrutiny, casting doubt on its fast-track approval and impacting patient hopes.

A chiropractor with millions of followers claims he can reverse dementia. As science eyes a breakthrough, we examine the hope, the hype, and the business.

Alico pivots from its 125-year citrus legacy to land development, and its CEO is set to face investors with a bold new plan for its 50,000 acres.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

Cleveland expands its AI security robot program, citing reduced crime. But as other cities watch, questions of cost, privacy, and effectiveness emerge.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

A new partnership with logistics giant Uniphar will bring Zevra's breakthrough NPC therapy, MIPLYFFA, to patients in underserved regions worldwide.